Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 6/20 | 0.58 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.51 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.50 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.50 |
| ▸ | CCNC | P24863 | 3/20 | 0.47 |
| ▸ | CDK8 | P49336 | 3/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL578559 | 0.99 | MAP4K4 (0.57) | MAP4K4SLC22A12MKNK1MKNK2CSNK2A2 | |
| SCHEMBL16211789 | 0.88 | SLC22A12 (0.50) | MAP4K4SLC22A12MKNK1MKNK2CSNK2A2 | |
| SCHEMBL16211927 | 0.87 | SLC22A12 (0.70) | MAP4K4SLC22A12CSNK2A2CSNK2BCCNC | |
| SCHEMBL578479 | 0.87 | SLC22A12 (0.55) | MAP4K4SLC22A12MKNK1MKNK2CCNC | |
| SCHEMBL10138319 | 0.86 | SLC22A12 (0.54) | SLC22A12MKNK1MKNK2CCNCCDK8 | |
| SCHEMBL10138336 | 0.86 | SLC22A12 (0.54) | MAP4K4SLC22A12MKNK1MKNK2CCNC | |
| SCHEMBL578353 | 0.86 | CHEK2 (0.55) | MAP4K4SLC22A12MKNK1MKNK2CCNC | |
| SCHEMBL10138576 | 0.86 | SLC22A12 (0.46) | MAP4K4SLC22A12MKNK1MKNK2CSNK2A2 | |
| SCHEMBL10138309 | 0.85 | SLC22A12 (0.53) | MAP4K4SLC22A12MKNK1MKNK2CCNC | |
| SCHEMBL16212390 | 0.84 | MAP4K4 (0.46) | MAP4K4SLC22A12MKNK1MKNK2CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991635-B1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | claimed |
| US-9586903-B2 | Isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | claimed |
| EP-2991635-A1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-03-09 | — | — | EP | claimed |
| US-20160046583-A1 | ISOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-02-18 | — | — | US | claimed |
| CN-105163727-A | Neurogenesis-stimulating isoquinoline derivatives | HOFFMANN LA ROCHE | 2015-12-16 | — | — | CN | claimed |
| WO-2014177596-A1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | claimed |
| US-8410273-B2 | Cyclic compound having substituted phenyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-02 | — | — | US | claimed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | claimed |
| EP-2418203-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | Daiichi Sankyo Company, Limited (JP) | 2012-02-15 | — | — | EP | claimed |
| EP-2991635-B1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | disclosed |
| EP-2991635-B1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-9586903-B2 | Isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586903-B2 | Isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586903-B2 | Isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2418203-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | Daiichi Sankyo Company, Limited (JP) | 2012-02-15 | — | — | EP | disclosed |
| EP-2418203-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | Daiichi Sankyo Company, Limited (JP) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010116915-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | 第一三共株式会社 (JP) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | BMP2, BMP4, BMP6 | MAP4K4 1563/4885SLC22A12 1300/4885MKNK1 546/4885 |
| US-20160046583-A1 | ISOQUINOLINE DERIVATIVES | CDR2, DRD2, HCRTR1 | MAP4K4 2189/4885SLC22A12 905/4885MKNK1 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.